It has been reported that ceritinib enhances the efficacy of trametinib, a MEK inhibitor, in BRAF/NRAS‐wt melanoma cell lines [38], which makes it plausible that ceritinib would not have any effect in BRAF‐mutated cells. Here, NRAS is linked to melanoma.